|

A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors

RECRUITINGPhase 1Sponsored by Ono Pharmaceutical Co., Ltd.
Actively Recruiting
PhasePhase 1
SponsorOno Pharmaceutical Co., Ltd.
Started2026-06-19
Est. completion2028-07
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07787208

Summary

This study is to evaluate the tolerability and safety of ONO-7429 in participants with unresectable advanced or recurrent solid tumors.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Participants with histologically or cytologically confirmed unresectable advanced or recurrent solid tumors.
2. Participants who are refractory or intolerant to standard therapy.
3. Participants with Eastern Cooperative Oncology Group Performance Status 0 or 1.
4. Participants with tumor tissue samples available for biomarker testing.

Exclusion Criteria:

1. Participants with a history or presence of severe hypersensitivity to any other antibody agents.
2. Participants with pericardial fluid, pleural effusion or ascites requiring treatment
3. Participants with uncontrolled tumor-related pain
4. Participants with severe peritoneal dissemination.
5. Participants with multiple primary cancers.
6. Participants with a history or presence of ILD or pulmonary fibrosis.

Conditions2

CancerSolid Tumors

Interventions1

ONO-7429

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.